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EVALUATION OF D-DIMER IN POSTMORTEM BLOOD USING THE 
SERATEC PMB TEST 
 
 
HUXI WANG 
 
ABSTRACT 
Biological material is a common type of evidence found at a crime scene, and body 
fluid identification is an essential process in crime scene investigation. One of the most 
common types of body fluids found is blood. After a stain has been presumptively 
identified as blood through the use of a colorimetric chemical test, additional testing may 
be necessary to better characterize the stain. SERATECÒ PMB Test is a relatively new 
lateral flow immunochromatographic assay that targets human hemoglobin and D-dimer 
simultaneously in order to distinguish peripheral blood and menstrual blood at the same 
time. Elevated levels of D-dimer, a fibrin degradation product, are found in menstrual 
blood, thrombosis formation and as part of the postmortem process.  
A previous study investigated levels of D-dimer in menstrual, peripheral and 
postmortem blood using the SERATECÒ  PMB Test. In this study, all postmortem blood 
samples showed positive results for both hemoglobin and D-dimer; all peripheral 
bloodstain samples from living individuals showed positive results for hemoglobin 
detection, and negative results for D-dimer detection; and most menstrual bloodstain 
samples showed positive D-dimer results. The results suggest that this assay could be 
considered a presumptive test for both postmortem blood and menstrual blood. However, 
as D-dimer concentrations vary between individuals, additional testing is necessary to 
vi 
conclusively distinguish postmortem blood, menstrual blood and peripheral blood from 
living individuals with especially high D-dimer levels.  
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1. INTRODUCTION 
1.1 Forensic Body Fluid Identification 
Body fluids are one of the more common types of biological material encountered 
at a crime scene, so body fluid identification is an essential process in forensic science. 
There are many different types of forensically relevant body fluids, including blood, urine, 
semen, saliva, and vaginal secretion. It is important to distinguish different types of body 
fluids taken from a crime scene, as it can demonstrate what type of crime may have 
happened and help guide the direction of the investigation1,2. For example, if semen stains 
are present at a crime scene, investigators would consider that a sexual assault case may 
have occurred. If bloodstains are present at a crime scene, investigators could examine the 
bloodstains further in order to assess whether a homicide, a suicide, or other types of crimes 
likely occurred at this particular crime scene. 
 
In order to determine whether further testing is warranted on a stain found in 
connection with a crime, it is essential to determine whether the stain is a body fluid. A 
reddish-brown stain could be blood, ketchup or red paint, so it is important to rule out non-
probative samples. Moreover, if there is a possibility of an animal bleeding at the crime 
scene, it may be necessary to distinguish animal blood from human blood.  
 
Many body fluids have a similar physical appearance when dried. For the purpose 
of quickly distinguishing what type of body fluid may be present, presumptive tests are 
utilized at the scene or in the laboratory. The simplest presumptive tests for blood are 
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colorimetric chemical tests, which are sensitive but lack of specificity1,3. These tests rely 
on the catalytic activity of heme groups present in hemoglobin. Some of the most 
frequently used presumptive blood tests by forensic examiners include the Kastle-Meyer 
test, which is both sensitive and relatively highly specific; leucomalachite green, which is 
less sensitive but more specific; tetramethylbenzidine, which is the active component of 
Hemastix; and orthotolidine, which is the active component of Combur test strips1–3. These 
chemical tests can be used interchangeably, and each has their own advantages and 
disadvantages. False positive results with certain plant peroxidases or chemical oxidants 
can occur, thus a second screening test for blood is often performed after the initial 
chemical test.  
 
In addition to chemical tests, the lateral flow immunochromatographic assay is a 
more recent and more specific screening test for human body fluids. While 
chromatographic strip immunoassays were at one time considered confirmatory tests, it is 
recognized now that non-human primates may cause a positive reaction as well as the 
presence of the target antigen in a body fluid other than the one the test was designed to 
detect4.  
 
The mechanism of an immunochromatographic assay for blood is based on antigen-
antibody reactions. Specifically, the sample well of the assay cassette contains a mobile 
monoclonal antibody that targets either human hemoglobin or human glycophorin A, both 
components of blood. The antibody is labeled with a dye that becomes visible under certain 
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conditions. If the sample tested contains human blood, an antigen-antibody complex is 
formed, which then migrates to the test area of the strip. The test area contains an 
immobilized polyclonal antibody that captures the antigen-antibody complex, forming an 
antibody-antigen-antibody sandwich. The accumulation of dye-labeled antibodies in the 
test area becomes visible as a pink band4.  
 
Though there are slight differences among various brands of 
immunochromatographic assays for blood, the principle is generally the same. Independent 
Forensics – RSIDÔ Blood uses the human glycophorin A antibody, while Abacus 
Diagnostics – HemaTraceÒ, SERATECÒ HemDirect and SERATECÒ PMB test use human 
hemoglobin antibody5–8. For the immunochromatographic assays that target human 
hemoglobin, a high dose hook effect is expected with very concentrated samples4,6–9. A 
high dose hook effect is a false negative result that occurs when an excessive number of 
antigens are present in the sample extract. When the concentration of hemoglobin is too 
high, the free hemoglobin that cannot bind due to lack of available antibody migrates 
towards the test area, and prevents the dye-labeled antigen-antibody complex from binding 
to the immobilized antibody at the test region, causing a negative result4. Therefore, sample 
dilution is necessary for highly concentrated samples. Since these 
immunochromatographic assays confirm the presence of human/primate blood, have no 
false reaction with peroxidases or oxidants, and are very sensitive and highly species-
specific, they are used as an ideal supplementary method combined with the chemical test 
for blood testing2.  
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1.2 Composition of the Blood 
 Blood contains both cellular and liquid components at the microscopic level. When 
a tube of whole blood is centrifuged, there are three major layers distinguishable via 
component density10. The top layer is the plasma, which is the least dense component, and 
contains soluble proteins and ions. The plasma layer occupies 55% of the whole blood, and 
it appears light yellow in color when it is isolated. The bottom layer contains erythrocytes, 
which are the densest component of the blood [Figure 1]. The volume of the erythrocytes 
in the blood is known as the hematocrit, which can indicate whether the individual has a 
fluid disorder11,12. For example, if an individual has a low hematocrit, it means the 
individual may have anemia due to a bleeding disorder or destruction of red blood cells; if 
the individual has a high hematocrit, it means the individual may have dehydration or 
polycythemia vera11. The middle layer is the buffy coat, which contains leukocytes and 
platelets, and only occupies less than 1% of whole blood. Although the middle layer is the 
smallest, it contains major components of the human body immune system and is 
responsible for various immune responses.  
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Figure 1. The major components of the whole blood. As whole blood is centrifuged, the major components 
are separated based on their mass. The top layer is the plasma, which occupies 48% to 63% of the whole 
blood. The middle layer is the buffy coat, which contains leukocytes and platelets, and only occupies less 
than 1% of the whole blood. The bottom layer contains red blood cells, which occupies 37% to 52% of the 
whole blood.  
Image source: OpenStax, Anatomy & Physiology. http://cnx.org/content/col11496/1.6/ June 19, 2013. 
 
Blood plasma is a sticky fluid that contains mostly water and over 100 different 
dissolved solutes, including nutrients, gases, hormones, wastes and products of cell 
activity, proteins, and inorganic ions. Plasma proteins weigh 8% of the whole plasma. They 
all contribute to osmotic pressure and maintain water balance in the blood and the tissues. 
However, they all have other functions, such as transport activity and enzymatic activity. 
The ratio of various proteins can subsequently be used as an age indicator of the 
bloodstain13.  
 
Blood contains dissolved fibrous proteins that become visible as fibrin strands 
during blood clotting. Fibrinogen is a plasma protein which occupies 4% of all plasma 
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proteins [Figure 2]. It is produced by the liver as an inactive form. With the enzymatic 
activity of thrombin, fibrinogen produces fibrin and forms fibrin threads of blood clots10. 
Clotting is normally regulated by restricting activation of the cascade to sites of exposed 
phospholipids, i.e. the damaged vascular wall14. The whole process is summarized as the 
coagulation cascade. 
 
 
Figure 2. The major proteins in the blood plasma. The most abundant plasma protein is albumin, which 
occupies 60% of the whole plasma proteins. There are four major types of globulins, and they occupy about 
35% in total. Fibrinogen occupies about 4% of all plasma proteins and the remaining 1% is a mixture of other 
proteins. 
 
The coagulation cascade is a series of complex biochemical events resulting in 
amplification of the cascade [Figure 3]. The usual complex of the cascade consists of active 
clotting factor, inactive precursor for the next step, co-factor to accelerate the reaction, 
calcium, and phospholipid complexes, i.e. cell membranes12,14. The initiation of 
coagulation requires several elements, including platelets, endothelial cells, and 
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leukocytes, whose activation provides a suitable surface for adhesion of clotting proteins. 
Once the vascular wall is damaged, P-selectin translocates from Weibel-Palade bodies, i.e. 
granules of endothelial cells, to the cell surface. P-selectin is an adhesion molecule, which 
binds to P-selectin glycoprotein ligand-1 in order to promote the activities of leukocytes 
and platelets on the surface of endothelial cells14. Weibel-Palade bodies release another 
protein called von Willebrand’s factor as well. This protein enhances platelet adhesion, as 
it binds to platelet membrane glycoprotein and supports the adhesion of platelets at the site 
of injury, promoting the process of platelet aggregation14. As the platelet-leukocyte 
complex aggregates at the site of injury, tissue factor (TF), which is a transmembrane 
glycoprotein, initiates the progression that leads to fibrin formation, since the final product 
of coagulation cascade is deposition of fibrin. At the final stage of coagulation, thrombin 
converts fibrinogen into fibrin threads that form the hemostatic plug. Tissue factor and von 
Willebrand’s factor are both pro-thrombotic mediators that favor clotting12,14.  
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Figure 3. The blood coagulation cascade. The flow chart demonstrates the reactions and conversions within 
the blood coagulation cascade. The major components, including platelets, thrombin, and fibrin, the 
inactivated form of major components, and the activators are labeled in the flow chart. Notice that the final 
product of the blood coagulation cascade is the stabilized, cross-linked fibrin clot.  
Image source: Graham Beards. https://commons.wikimedia.org/wiki/File:Coagulation_in_vivo.png June 5, 
2012. 
 
 
1.3 Fibrinolysis and D-dimer 
 The coagulation cascade is a process that is tightly regulated by various proteins 
and protein factors. If the clotting process is not regulated, a thrombus may form 
inappropriately15,16. Hypercoagulable states are accompanied by thrombin and fibrin 
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production. Factor XIII, which is also known as fibrin stabilizing factor, is an enzyme that 
is responsible for crosslinking fibrin into an insoluble clot17. Hypercoagulability refers to 
an abnormally high tendency of the blood to clot, and is typically caused by alterations in 
coagulation factors16.  
 
When the site of injury is healed, the clot will be lysed via the process of 
fibrinolysis. Fibrinolysis is a highly regulated enzymatic process that prevents unnecessary 
accumulation of intravascular fibrin and enables the removal of thrombi15. Similar to the 
coagulation cascade, fibrinolysis is strictly controlled by a series of proteins and receptors, 
including various inhibitors and cofactors18. The purpose of fibrinolysis is to prevent blood 
clots from growing and becoming problematic, which would lead to severe cardiovascular 
diseases.  
 
Fibrinolysis begins when plasminogen activators convert plasminogen into 
plasmin, which then breaks down fibrin into soluble fibrin degradation products (also 
known as FDP)19. Plasmin is generated from the zymogen plasminogen on the surface of 
the fibrin clot or on the cell surface, by either tissue-type plasminogen activator (tPA) or 
urokinase-type plasminogen activator (uPA). tPA-mediated plasminogen activation is 
primarily involved in fibrin dissolution in the circulation of the blood, whereas uPA binds 
to a specific cellular urokinase-type plasminogen activator receptor (u-PAR) in order to 
enhance the activation of cell-bound plasminogen16,18,20. All plasminogen activators 
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convert plasminogen into activated plasmin by cleaving a single Arg561-Val562 peptide 
bond, a process by which two plasmin molecules are formed16,18.  
 
The concentration of plasmin in plasma is controlled by the concentration of 
plasminogen activators21. The system is regulated at two levels [Figure 4]. Type 1 
plasminogen activator inhibitor (PAI-1) inhibits the plasminogen activators, whereas alpha 
2-antiplasmin inhibits plasmin to prevent forming fibrin degradation products from fibrin. 
Although there are various activators and inhibitors in the blood to regulate fibrinolysis, 
the fibrin degradation product level is not always correlated with the concentration of 
plasminogen activator in the blood22. Nevertheless, the concentration of FDP can be an 
index of fibrinolytic activity level, since FDP is the final product of fibrinolysis. 
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Figure 4. Fibrinolysis and its regulation in blood. Plasminogen activators convert plasminogen into 
plasmin, and this process is regulated by PAI-1. Plasmin then further degrades fibrin into fibrin degradation 
products, which include D-dimer, and this process is regulated by a2-antiplasmin, which is an inhibitor of 
plasmin. 
 
Fibrin degradation yields a series of high molecular weight compounds. When 
fibrin polymers are cleaved by plasmin at the D fragment site, the resulting D-dimer 
fragment reflects the degree of thrombosis and the activity of plasmin20. D-dimer is an 
intermediate product of fibrin metabolism, which is an epitope that is present only after the 
crosslinking of the fibrin network and subsequent lysis by plasmin19. The presence of D-
dimer in the blood can be regarded as the indicator of the prior existence of a blood clot, 
which is also an indication of a coagulation cascade taken place. 
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1.4 D-dimer in Clinical Practice 
When the blood coagulation cascade and the fibrinolytic system do not work as 
they are supposed to, excessive amounts of thrombin form, leading to thrombosis23. 
Thrombosis can lead to blockage of blood vessels and even to myocardial infarction and 
stroke. The morbidity and mortality of venous thromboembolic disorders are considerable. 
Clinically, patients with venous thromboembolism (VTE) can be defined as presenting 
with deep-vein thrombosis (DVT), pulmonary embolism (PE), or both. Pulmonary 
thromboembolism is the clinical entity due to the obstruction of pulmonary vessels by 
venous thrombi, which leads to various clinical manifestations and is difficult for early 
diagnosis23. VTE is currently the leading cause of preventable hospital death and a leading 
cause of maternal mortality in the United States24.  
 
D-dimer has been regarded as an indicator of fibrinolysis and coagulation 
activation, and an indirect biomarker of thrombotic activity25. Unlike other fibrin 
degradation products, D-dimer fragments are end products of the action of plasmin on 
cross-linked fibrin. D-dimer tests have been used in the evaluation of suspected PE and 
suspected DVT for the past two decades26.  
 
Research has shown that D-dimer is a sensitive marker for thrombosis but lacks 
specificity, therefore it cannot be used to make a positive diagnosis of VTE27. However, 
D-dimer has a high negative predictive value and can be used as an exclusionary test, as it 
can be used to rule out VTE27. For example, D-dimer testing and compression ultrasound 
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imaging allow for safe and convenient investigation of suspected lower-extremity 
thrombosis. Patients with low pretest probability and a negative D-dimer test result can 
have proximal DVT excluded without the need for further diagnostic imaging28.  
 
Nevertheless, the D-dimer test has little clinical value as an exclusion test for VTE 
when used in patients who are older than 80 years old29. The explanation and mechanism 
for the increasing levels of D-dimer in the elderly are still uncertain30. One hypothesis of 
the elevated D-dimer level in elderly people is that chronic inflammation is associated with 
an upregulation of coagulation and reactive compensatory fibrinolysis, which leads to 
excess production of D-dimer30. Although D-dimer tests do have limitations in specific 
patient categories or clinical settings, such as a patient with a previous VTE or a patient in 
pregnancy, D-dimer tests remain highly sensitive in those situations26. 
 
1.5 D-dimer in a Forensic Perspective 
 The current methods of detecting D-dimer in blood in the forensic science field 
mainly focus on menstrual blood identification. Distinguishing menstrual blood from 
peripheral blood at a scene could provide important contextual information about the 
incident or provide investigative leads. From research conducted in 1996, Japanese 
scientists determined the difference in concentration of D-dimer among postmortem blood, 
peripheral blood, and menstrual blood. They found that menstrual blood and postmortem 
blood had similar high plasma D-dimer concentrations, whereas peripheral blood had 
extremely low plasma D-dimer concentrations that were considered insignificant31. 
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Therefore, positive detection of D-dimer in a blood sample could be interpreted as 
indicating the presence of either menstrual blood or postmortem blood. If there are D-
dimer-positive bloodstains present at a scene but no logical source to attribute them to, 
investigators should reconsider the direction of their investigation. 
 
Postmortem blood (i.e. blood that exits the body at some point after death) is not as 
commonly found at a crime scene as antemortem or perimortem peripheral blood. 
Investigators tend to distinguish blood from other bodily fluids, but they might not further 
identify what type of blood it is. Distinguishing whether the blood present at a crime scene 
is antemortem or postmortem can be particularly important in cases involving possible 
violence when there is no victim or body present at the scene. Since D-dimer is found in 
elevated levels in postmortem blood, its identification could determine whether the blood 
at the scene was from a living or deceased individual. 
  
SERATECÒ PMB Test is a relatively new immunochromatographic assay that 
targets human hemoglobin and D-dimer simultaneously in order to distinguish peripheral 
blood and menstrual blood at the same time [Figure 5]8. The primary purpose of 
SERATECÒ PMB Test is to presumptively identify menstrual blood. This duplex assay 
contains four monoclonal antibodies and two polyclonal antibodies. Two gold-labeled 
monoclonal antibodies for identification of human hemoglobin and D-dimer are located in 
the sample well area, whereas the other two monoclonal antibodies for the antibody-
antigen-antibody sandwich complex assay are located at the two result lines, respectively. 
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The two polyclonal antibodies are located at the control line. The cassette of the assay 
contains one sample well and one result window with a control line (labeled “C” for 
control), a result line for human hemoglobin (labeled “P” for peripheral blood), and a result 
line for D-dimer (labeled “M” for menstrual blood)8. If the control line is not visible at the 
completion of the assay, the test is considered invalid and should be performed again using 
a new test cassette8. 
 
 
Figure 5. Interpretation of results shown of SERATECÒ PMB Test. The major components of the test 
cassette are labeled. One control line and two result lines will appear in the result window if both human 
hemoglobin and D-dimer are present in the test sample. The control line must always be visible in order to 
show the validity of the test. 
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1.6 Study Purpose 
 The purpose of this project was to investigate the detection of accumulated D-dimer 
in postmortem blood using the SERATECÒ  PMB Test for menstrual blood. The project 
also discusses the feasibility and usefulness of D-dimer detection in postmortem blood for 
forensic purposes. Moreover, the project attempts to look for the relationships between D-
dimer accumulation in postmortem blood and other factors, such as age, time between 
death and blood collected, and site of blood collection. 
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2. MATERIALS AND METHODS 
2.1 Sample Collection 
Twenty postmortem blood samples were collected during autopsy and stored frozen 
in vacuum blood collection tubes until use. All liquid blood samples were stored in the 
freezer at -16 °C.  
 
 
Table 1. Postmortem blood samples. Information about postmortem blood sample donors including gender, 
age, time between death and autopsy, and site of blood collection. The age of the donors ranged from 21 to 
90 years old. The time between death and autopsy ranged from 4 hours and 5 minutes to more than 3 days. 
The site of blood collection was noted, and “N/A” means the site of collection was unknown. 
 
 
PM Sample Gender Age Time between Death and Autopsy Site of Collection 
PM001 Female N/A N/A N/A 
PM002 Male 60 1 day N/A 
PM003 Male 44 1 day N/A 
PM004 Male 58 23 hours and 30 minutes Cavity 
PM005 Male 75 1 day N/A 
PM006 Male 66 3 days Heart 
PM007 Male 75 1 day and 7 hours and 9 minutes N/A 
PM008 Male 59 21 hours and 33 minutes Cardiac 
PM009 Female 58 1 day Chest 
PM010 Female 58 3 days Chest 
PM011 Female 58 1 day N/A 
PM012 Female 52 3 days and 19 hours N/A 
PM013 Male 54 1 day and 14 hours and 8 minutes N/A 
PM014 Male 58 1 day N/A 
PM015 Male 21 18 hours N/A 
PM016 Male 60 2 days Cardiac 
PM017 Female 83 8 hours and 34 minutes Jugular vein 
PM018 Female 90 4 hours and 5 minutes Jugular vein 
PM019 Male 30 1 day and 19 hours and 45 minutes N/A 
PM020 Male 52 1 day and 21 hours and 34 minutes N/A 
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In order to conduct the validation and the investigation under controlled conditions, 
both peripheral blood and menstrual blood were included in the study. The menstrual blood 
samples were regarded as the positive control group, whereas the peripheral blood samples 
were regarded as the negative control group. 
 
Ten peripheral bloodstain samples were collected from 6 female volunteers and 4 
male volunteers in accordance with the Boston University School of Medicine Institutional 
Review Board. Four samples were received on a cotton swatch, four samples were received 
on a gauze pad, and two samples were received on filter paper. All peripheral bloodstain 
samples were stored in the freezer at -16 °C upon receipt. 
 
Ten menstrual bloodstain samples were collected from 5 volunteers. For each 
donor, samples from two separate days during one menstrual period were collected. All 
menstrual bloodstain samples were received on a cotton swatch. All samples were stored 
in the freezer at -16 °C. 
 
2.2 Test Preparation 
The immunochromatographic assay used for the experiments was the SERATECÒ 
PMB Test (SERATEC GmbH, Göttingen, Germany), which detects human hemoglobin 
and D-dimer simultaneously. The test kit contains buffer solutions for liquid sample 
dilution or dried sample extraction [Figure 6]. The optimal sensitivity for human 
hemoglobin is reported to be 20 ng/mL, and for D-dimer is 400 ng/mL8. The possibility of 
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a high dose hook effect in hemoglobin detection has been previously reported; therefore, 
if a high dose hook effect was suspected,  a dilution of the original sample was made and 
a test of this diluted sample was performed. All test components were brought to ambient 
temperature, including blood samples and buffer solutions, prior to testing.  The result was 
read after 10 minutes of incubation at room temperature.  
 
 
Figure 6. The SERATECÒ PMB test (opened). The cassette (left) is the immunochromatographic assay. 
The circle well is the sample well, where the sample is put in. The rectangular section is the result window, 
where shows test results. “C” line is the control line. “P” line is the result line for human hemoglobin, as the 
“P” means “peripheral blood”. “M” line is the result line for D-dimer, as the “M” means “menstrual blood”. 
The disposable pipet (middle) is included in the test kit. The buffer solution (right) is included in the test kit 
as well. 
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2.3 Test Procedures 
2.3.1 Postmortem Blood Samples 
Bloodstains were produced by using a disposable pipet and allowing two drops of 
blood to soak into a cotton swatch [Figure 7]. Before making bloodstains, blood samples 
were vortexed for 5 seconds. Three individual stains were produced for each blood sample. 
The bloodstain samples were dried and stored at room temperature for 24 hours. For each 
bloodstain, a 1 cm ´ 1 cm area of stain was measured by a ruler and cut by a scalpel. Both 
the ruler and scalpel were sterilized every time before cutting a bloodstain. Each cutting 
was put into 1.5 mL of buffer solution provided by SERATECÒ PMB Test Kit for 
extraction. The extraction time was 60 minutes, then 120 µL of extracted solution was 
added into SERATECÒ PMB Test sample well by using a pipet. After 10 minutes of 
incubation at room temperature, the test result was recorded and photographed.  
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Figure 7. Preparation of postmortem blood samples. The liquid postmortem blood samples were dropped 
on a piece of cotton swab three times for each sample. For each “sample circle”, there were two to three drops 
of blood. The size of the circle depended on the viscosity of the blood. Note the color differences among the 
samples. In most of the “appeared-black” liquid blood samples, there were blood clots present within the 
liquid sample in the sample tube. 
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2.3.2 Peripheral Bloodstain Samples and Menstrual Bloodstain Samples 
For each stain, a 1 cm ´ 1 cm area of stain was measured by a ruler and cut by a 
scalpel. If the amount of the original bloodstain sample was too small, a 0.5 cm ´ 0.5 cm 
area of stain was measured and cut. Both the ruler and scalpel were sterilized every time 
before cutting a bloodstain. Each cutting was put into 1.5 mL of buffer solution provided 
by SERATECÒ PMB Test Kit for extraction. The extraction time was 60 minutes, then 120 
µL of extracted solution was added into SERATECÒ PMB Test sample well by using a 
pipet. After 10 minutes of incubation at room temperature, the test result was recorded and 
photographed.  
 
2.3.3 Dilution Process 
For samples that appeared susceptible to the high dose hook effect, 1000 µL of 
solution from the original sample-buffer solution was added into 500 µL new buffer 
solution and mixed well, then 120 µL of new sample-buffer solution was added into 
SERATECÒ PMB Test cassette for another round of testing. The test result was recorded 
and photographed. 
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3. RESULTS  
3.1 Postmortem Blood Samples 
Postmortem blood samples were collected from cadavers ranging from 21 to 90 
years old. The time between death and autopsy varied from less than a day to four days. 
Seven of postmortem blood samples were collected from female donors, and 13 were 
collected from male donors. None of the donors had a reported medical history of vascular 
diseases nor did any report evidence of antemortem thromboembolism, air embolism, 
pulmonary thromboembolism, or thrombi in atria or ventricles. 
 
All of the postmortem blood samples (n = 20) reacted positively for the presence 
of both hemoglobin and D-dimer [Table 2]. For 6 of the cassettes, the hemoglobin line was 
very faint, making it difficult to visualize.  The high dose hook effect was suspected in 
these samples, therefore, a dilution process was performed for each individual sample and 
the testing was repeated [Figure 8]. Upon retesting, all of the diluted postmortem blood 
samples (n = 6) reacted positively for both hemoglobin and D-dimer presence with pink 
lines that were readily visible [Table 3]. Therefore, the positive rate for D-dimer presence 
in postmortem blood samples tested by SERATECÒ PMB Test was 100%. Interestingly, 
band intensity in both hemoglobin detection and D-dimer detection varied among samples 
[Figure 9].  
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Table 2. SERATECÒ PMB Test results of postmortem blood samples. The results of D-dimer detection 
are color-labeled in the table according to intensity. Dilution was performed when the intensity of hemoglobin 
results were weak, possibly due to a high dose hook effect. Each sample was tested in triplicate, and most 
samples showed consistent results among triplicates. 
 
 
Table 3. SERATECÒ PMB Test results of diluted postmortem blood samples. The results of D-dimer 
detection are color-labeled in the table according to intensity. Initially these samples showed weak positive 
bands for hemoglobin. After dilution, all samples showed strong or moderate intensity in both hemoglobin 
and D-dimer detection. Each sample was tested in triplicate, and most samples showed consistent results 
among triplicates. 
 
PM 
Sample 
PMB Test 
Trial 1 Trial 2 Trial 3 
Hemoglobin D-Dimer Hemoglobin D-Dimer Hemoglobin D-Dimer 
PM001 Strong + Strong + Strong + Strong + Strong + Strong + 
PM002 Weak + Strong + Weak + Strong + Weak + Strong + 
PM003 Strong + Strong + Strong + Strong + Strong + Strong + 
PM004 Weak + Strong + Weak + Strong + Weak + Strong + 
PM005 Strong + Strong + Strong + Strong + Strong + Strong + 
PM006 Moderate + Moderate + Moderate + Moderate + Moderate + Moderate + 
PM007 Strong + Strong + Strong + Strong + Strong + Strong + 
PM008 Weak + Strong + Weak + Strong + Weak + Strong + 
PM009 Weak + Strong + Weak + Strong + Weak + Strong + 
PM010 Strong + Strong + Strong + Strong + Strong + Strong + 
PM011 Strong + Strong + Strong + Strong + Strong + Strong + 
PM012 Weak + Strong + Weak + Strong + Weak + Strong + 
PM013 Weak + Strong + Weak + Strong + Weak + Strong + 
PM014 Strong + Strong + Strong + Strong + Strong + Strong + 
PM015 Weak + Strong + Weak + Strong + Weak + Strong + 
PM016 Moderate + Strong + Strong + Strong + Moderate + Strong + 
PM017 Moderate + Moderate + Moderate + Moderate + Moderate + Moderate + 
PM018 Strong + Strong + Strong + Strong + Strong + Strong + 
PM019 Strong + Strong + Strong + Strong + Strong + Strong + 
PM020 Moderate + Strong + Strong + Strong + Moderate + Strong + 
PM-Diluted 
Sample 
PMB Test 
Trial 1 Trial 2 Trial 3 
Hemoglobin D-Dimer Hemoglobin D-Dimer Hemoglobin D-Dimer 
PM002-D Strong + Strong + Moderate + Strong + Strong + Strong + 
PM004-D Moderate + Strong + Moderate + Strong + Moderate + Strong + 
PM008-D Strong + Strong + Strong + Strong + Strong + Strong + 
PM009-D Moderate + Strong + Moderate + Strong + Moderate + Strong + 
PM012-D Moderate + Moderate + Moderate + Strong + Moderate + Strong + 
PM013-D Moderate + Moderate + Moderate + Moderate + Moderate + Moderate + 
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A.  
B.  
Figure 8. High dose hook effect for hemoglobin detection of SERATECÒ PMB Test for postmortem 
bloodstain sample (comparison of the original sample and diluted sample). (A). For the original sample, 
the control line was very clearly visible, which indicated that this test was valid. The hemoglobin result line 
was so faint that it was barely visible. The D-dimer result line was clearly visible. The background color of 
the result window was light-reddish, which may indicate that the concentration of the sample was too high. 
A high dose hook effect was suspected and a dilution process was performed for this sample. (B). In the 
diluted sample, the hemoglobin result line was more clearly visible than that in the original sample, and the 
background color of the result window was clear. 
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Figure 9. Strong positive results for both hemoglobin and D-dimer detection of SERATECÒ PMB Test 
for postmortem bloodstain sample. The control line was very clearly visible, which indicated that this test 
was valid, and both result lines were clearly visible. The background color of the result window was clear, 
which may indicate that the concentration of the blood sample was not too high for the test. No dilution 
process was needed for this sample. 
 
3.2 Peripheral Bloodstain Samples 
All peripheral blood samples were collected directly onto a clean substrate and 
allowed to air dry. The type of substrates included cotton swatches, filter paper, and gauze 
pads. All substrates were white in color and no other stains or contaminants were present. 
No preservative was added into any peripheral bloodstain sample. No information 
regarding medical history was collected.  
 
All of the peripheral bloodstain samples (n = 10) reacted positively for the presence 
of hemoglobin, while none of the peripheral bloodstain samples reacted positively for the 
presence of D-dimer [Table 4]. Nine peripheral bloodstain samples presented strong 
positive signals, and one peripheral bloodstain sample gave a moderate positive signal for 
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hemoglobin [Figure 10]. No additional dilution was required for peripheral bloodstain 
samples since no high dose hook effect was observed among peripheral bloodstain samples. 
 
Table 4. SERATECÒ PMB Test results of peripheral bloodstain samples. All samples showed a negative 
result in D-dimer detection and 90% of those samples showed a strong intensity in hemoglobin detection. No 
further dilution was needed for any sample in this group. 
 
PB Sample 
PMB Test 
Trial 1 Trial 2 Trial 3 
Hemoglobin D-Dimer Hemoglobin D-Dimer Hemoglobin D-Dimer 
PB001 Moderate + Negative Moderate + Negative Moderate + Negative 
PB002 Strong + Negative Strong + Negative Strong + Negative 
PB003 Strong + Negative Strong + Negative Strong + Negative 
PB004 Strong + Negative Strong + Negative Strong + Negative 
PB005 Strong + Negative Strong + Negative Strong + Negative 
PB006 Strong + Negative Strong + Negative Strong + Negative 
PB007 Strong + Negative Strong + Negative Strong + Negative 
PB008 Strong + Negative Strong + Negative Strong + Negative 
PB009 Strong + Negative Strong + Negative Strong + Negative 
PB010 Strong + Negative Strong + Negative Strong + Negative 
 
 
Figure 10. Strong positive result for hemoglobin detection of SERATECÒ PMB Test for peripheral 
bloodstain sample. The control line was very clearly visible, which indicated that this test was valid. Only 
the hemoglobin result line was visible in comparison to the D-dimer result line. There was no line visible for 
D-dimer detection, which indicated that no detectable amount of D-dimer present in this particular sample. 
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3.3 Menstrual Bloodstain Samples 
All menstrual blood samples were collected in the form of bloodstains on a white 
panty liner or cotton swatch. No preservative was added into any menstrual bloodstain 
sample, nor were any of the donors asked about their medical history of vascular disease. 
 
All of the menstrual bloodstain samples (n = 10) reacted positively for the presence 
of hemoglobin. Eight menstrual bloodstain samples also reacted positively for D-dimer 
[Table 5]. One menstrual bloodstain sample that initially showed very faint bands (MB001-
Day3) in hemoglobin detection due to a suspected high dose hook effect was diluted for a 
second screening, and the results showed positive signals for both hemoglobin and D-dimer 
presence, although only 1 of the triplicate samples demonstrated an increase in band 
intensity [Table 5]. Only one sample showed strong positive results for both hemoglobin 
and D-dimer detection [Figure 11]. Five menstrual bloodstain samples showed weak 
positive signals for D-dimer presence. 
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Table 5. SERATECÒ PMB Test results of menstrual bloodstain samples. The results of D-dimer 
detection are color-labeled according to intensity. Each sample was tested in triplicate, and most samples 
showed consistent results among triplicates. Dilution was needed for one sample, as it had weak intensity in 
hemoglobin detection, and a high dose hook effect was suspected.  
 
MB Sample 
PMB Test 
Trial 1 Trial 2 Trial 3 
Hemoglobin D-Dimer Hemoglobin D-Dimer Hemoglobin D-Dimer 
MB001-Day3 Weak + Weak + Weak + Weak + Weak + Weak + 
MB001-Day4 Moderate + Weak + Moderate + Weak + Moderate + Weak + 
MB002-Day2 Strong + Negative Strong + Negative Strong + Negative 
MB002-Day3 Strong + Negative Strong + Negative Strong + Negative 
MB003-Day2 Strong + Weak + Strong + Weak + Strong + Weak + 
MB003-Day3 Strong + Weak + Strong + Weak + Strong + Negative 
MB004-Day2 Strong + Weak + Strong + Weak + Strong + Weak + 
MB004-Day3 Moderate + Moderate + Moderate + Moderate + Moderate + Moderate + 
MB005-Day1 Strong + Moderate + Strong + Moderate + Strong + Moderate + 
MB005-Day3 Strong + Strong + Strong + Strong + Strong + Strong + 
 
 
 
 
Table 6. SERATECÒ PMB Test results of diluted menstrual bloodstain samples. The results of D-dimer 
detection are color-labeled according to intensity. Trial 1 and Trial 2 had the sample result as the 
corresponding undiluted sample result. Both hemoglobin intensity and D-dimer intensity increased in the 
diluted sample. 
 
MB-Diluted Sample 
PMB Test 
Trial 1 Trial 2 Trial 3 
Hemoglobin D-Dimer Hemoglobin D-Dimer Hemoglobin D-Dimer 
MB001-Day3-D Weak + Weak + Weak + Weak + Moderate + Moderate + 
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Figure 11. Negative result for D-dimer detection of SERATECÒ PMB Test for menstrual bloodstain 
sample. The control line was very clearly visible, which indicated that this test was valid. Only the 
hemoglobin result line was visible in comparison to the D-dimer result line. There was no line visible for D-
dimer detection, which indicated no detectable amount of D-dimer present in this particular sample. The 
background of the result window was whitish, which may indicate that the concentration of the sample was 
good for testing.  
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4. DISCUSSION 
4.1 Test Result Analysis 
4.1.1 Postmortem Blood Samples 
All postmortem samples showed positive results in D-dimer detection, suggesting 
that D-dimer could be a suitable indicator to differentiate postmortem blood from 
antemortem peripheral blood. Previous research has shown that menstrual blood and 
postmortem blood could not be distinguished by FDP detection as both contain large 
amounts of FDP, thus the high positive result rate for D-dimer among postmortem blood 
samples was expected31. The release of factors that activate postmortem fibrinolysis from 
the vascular wall promotes fibrinolytic activity, leading to the accumulation of D-dimer in 
the samples22.  
 
During autopsy or body preservation, postmortem blood samples were taken from 
the deceased’s heart, the thoracic cavity, or the jugular vein. Among postmortem blood 
samples taken from different parts of the body cavity, the FDP level has been reported to 
be higher in the heart than in the thoracic cavity in cadavers22. For the two samples (PM006 
and PM017) that only showed moderate intensity in D-dimer detection, both donors could 
be considered elderly persons (66-years-old and 83-years-old). It is known that the level of 
D-dimer and the prevalence of elevated D-dimer increases with age, so the origin of FDP 
detected from elderly donors should be considered, as the detected FDP could be either 
from antemortem fibrinolysis or from postmortem fibrinolysis30. According to the test 
results, the D-dimer concentration was detectable among all the postmortem samples, with 
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corresponding donor age ranging from 21 to 90 years old, thus detectable amounts of D-
dimer in postmortem blood were present regardless of the age of the donor.  
 
For the samples that had the suspected high dose hook effect and underwent the 
dilution process (PM002, PM004, PM008, PM012, and PM013), the physical appearance 
of these bloodstains were similar, as they all appeared very dark reddish-brown (nearly 
black) in color and had a high fluid viscosity. The fluid with a high viscosity needed more 
liquid drops to make a 1 cm ´ 1 cm stain. Before the dilution process, the original samples 
showed a weak intensity in hemoglobin band and a strong intensity in D-dimer band. Most 
of the hemoglobin bands were too faint to be readily distinguishable. After the dilution 
process, the diluted samples showed either moderate or strong intensity in both hemoglobin 
and D-dimer bands.  Therefore, the amount of hemoglobin in the fixed area would be higher 
in more viscous blood, and a suspected high dose hook effect was somewhat expected. 
 
The time interval between death and blood collection varied among samples, 
ranging from 4 hours to 4 days. There were 11 samples for which the blood was collected 
within one day between time of death and time of autopsy. Among these 11 samples, 10 of 
them gave a strong intensity result for D-dimer detection, and only one sample (PM017) 
gave a moderate intensity in D-dimer detection. The time interval of PM017 was the second 
shortest at 8 hours and 34 minutes, and it is possible that postmortem fibrinolysis did not 
accumulate a lot of D-dimer in this short period of time. One study that investigated the 
relationship between the FDP level and time after death in rats stated that FDP increased 
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rapidly and reached a maximum value 12 to 20 hours after death in all rats, regardless of 
the cause of death22. While that study did not investigate FDP levels beyond one day 
postmortem, D-dimer was detectable via immunochromatographic assay up to four days 
after death in the current study.  
 
4.1.2 Menstrual Bloodstain Samples 
Two menstrual bloodstain samples showed a negative result for D-dimer detection 
in all three trials (MB002-Day2 and MB002-Day3); these two samples came from the same 
donor on two consecutive days (menses day 2 and day 3). A possible reason why there was 
no detectable D-dimer present was that the D-dimer concentration for that donor was too 
low to reach the threshold value of the immunochromatographic assay. According to the 
manufacturer, the sensitivity of D-dimer in the PMB Test is 400 ng/mL8. One previous 
study stated that variation in D-dimer levels between different individuals occurred with 
samples collected on different days, and the variation observed between donors, sample 
days, and concentration of D-dimer could be a result of differing amounts of material 
recovered from each substrate 32. Trial 3 of MB003-Day3 gave a negative result for D-
dimer detection, but both trial 1 and 2 gave a weak positive result. This discrepancy could 
be explained by the amount of menstrual blood extracted from the cotton swatch being 
different among these three trials, influencing the amount of D-dimer present for detection 
by SERATECÒ PMB Test. MB005-Day1 and MB005-Day3 were taken from the same 
donor on two days (menses day 1 and day 3). All trials of MB005-Day1 showed a moderate 
intensity in D-dimer band, whereas all trials of MB0005-Day3 showed a strong intensity 
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in D-dimer band. This difference between band intensities suggested that variation in D-
dimer levels occurs within a single individual at different time points. Therefore, the 
variation in results of D-dimer detection in menstrual bloodstain samples was not 
unexpected, since D-dimer concentration can be influenced by various factors. 
 
4.1.3 Peripheral Bloodstain Samples 
All peripheral bloodstain samples from living individuals showed positive results 
for hemoglobin detection, and negative results for D-dimer detection. No medical history 
regarding vascular diseases was asked of the donors. In healthy adults, D-dimer 
concentration in liquid peripheral blood is about 47 ng/mL, and in peripheral bloodstains 
D-dimer concentration is about 11 ng/mL33. The amount of D-dimer reported in peripheral 
blood of healthy adults is therefore negligible and far below the threshold (400 ng/mL) for 
D-dimer sensitivity of SERATECÒ PMB Test. Although some health conditions can 
elevate D-dimer levels in blood, such as deep vein thrombosis, cancer and coronary heart 
disease, these health conditions may not cause the level of D-dimer in peripheral blood to 
reach that found in menstrual or postmortem blood32. Therefore, the negative results of D-
dimer detection in peripheral bloodstain samples were expected. 
 
4.2 Forensic Feasibility of D-dimer Detection in Postmortem Blood 
 One previous study that used SERATECÒ PMB Test showed that 70% of the 
postmortem samples (n = 10) gave positive results for both hemoglobin and D-dimer 
presence9. However, after using the same immunochromatographic assay and technique, 
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100% of the postmortem samples (n = 20) reacted positively for both hemoglobin and D-
dimer detection in the current study. The discrepancy between the two studies may be 
related to the postmortem interval or cause of death, as these are largely unknown for most 
of the donor samples. Nevertheless, this particular immunochromatographic assay was 
initially designed for menstrual blood identification by identifying both D-dimer and 
hemoglobin simultaneously, yet has a high rate of D-dimer detection in postmortem 
peripheral blood. As a result, this test can be considered as a presumptive test for both 
menstrual blood and postmortem blood identification. 
 
To distinguish menstrual blood and postmortem blood containing D-dimer, further 
investigation would be needed. For example, microscopy can be used to examine whether 
there are substantial epithelial cells present within the blood sample, which would be 
expected only for menstrual blood samples34. DNA profiling could determine the sex of 
the origin of the blood. If the blood found contains D-dimer and has both X and Y 
chromosomes, menstrual blood can be ruled out. 
 
All things considered, D-dimer detection is feasible as a preliminary screening 
method for identifying menstrual or postmortem blood. Further analyses using DNA and 
information about age and medical history should be combined with D-dimer detection in 
order to further categorize bloodstains with a higher degree of specificity. 
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4.3 Postmortem Biochemical Changes 
 In one study, researchers reported that myoglobin concentration in postmortem 
blood increased soon after death, which should be considered as an additional tool for 
discrimination of postmortem blood from menstrual blood31. The study showed that 
myoglobin concentration in postmortem bloodstains was 4000-7500 times higher than that 
of peripheral bloodstains and menstrual bloodstains.  
 
Furthermore, cause of death could affect fibrinolytic activity. One study showed 
that after rapid death from endogenous or exogenous causes, the plasma catecholamine 
level and fibrinolytic activity were high in human subjects22. Exogenous acute death 
included drowning, carbon monoxide poisoning, hanging, injury of the central nervous 
system, blood loss, and cyanide poisoning. Among exogenous acute deaths, the highest 
amount of FDP detected was from hanging, and the value was 41.8 mg/mL, whereas the 
lowest amount of FDP detect was from cyanide poisoning, with a value of 2.0 mg/mL22. 
Endogenous acute death included intracranial hemorrhage, idiopathic cardiomyopathy, 
myocardial infarction, and hemopericardium. Among endogenous acute death, the highest 
amount of FDP detected was from myocardial infarction (27.0 mg/mL), whereas the lowest 
amount of FDP detected was from hemopericardium (5.6 mg/mL)22. However, if the 
individual died due to endogenous chronic death, such as pneumonia and liver cirrhosis, 
the plasma catecholamine level and fibrinolytic activity were much lower than in acute 
death. Among endogenous chronic death, the highest amount of FDP detected was from 
carcinoma (0.375 mg/mL), whereas the lowest amount of FDP detected was from liver 
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cirrhosis (0.125 mg/mL)22. The difference in FDP level between acute death and chronic 
death was significant, suggesting that the level of fibrinolytic products can assist in 
determining the cause and/or manner of death to some degree. 
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5. CONCLUSIONS 
SERATECÒ PMB Test showed a one hundred percent positive rate in D-dimer 
detection in 20 postmortem blood samples, regardless of donor’s gender, age, time interval 
between death and autopsy, and site of collection, although the test’s original purpose was 
to differentiate menstrual blood from peripheral blood. All peripheral bloodstain samples 
showed positive results for hemoglobin detection only, and most menstrual bloodstain 
samples gave positive results for both hemoglobin and D-dimer detection. Thus, this test 
could be considered as a presumptive test for both postmortem blood and menstrual blood. 
However, D-dimer concentrations vary between individuals, necessitating secondary 
screening tests or confirmatory tests to distinguish postmortem blood, menstrual blood and 
peripheral blood from living individuals with especially high D-dimer levels. Donor age 
showed no influence in the presence of D-dimer in postmortem samples from this research, 
but a medical history of thrombosis and advanced age should be considered as potential 
factors affecting the D-dimer level in the blood.  
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6. DIRECTIONS FOR FUTURE STUDY AND INVESTIGATION 
The sample size of all groups in this study was not very large. For future study, the 
postmortem blood sample size should increase for more accurate results. In order to 
evaluate any relationship between the amount of D-dimer and the deceased’s age and time 
since death, the concentration of D-dimer should be measured quantitatively. Further, the 
SERATECÒ PMB Test user instructions report the possibility of encountering the high 
dose hook effect with respect only to hemoglobin detection. It is worth investigating 
whether D-dimer detection is also susceptible to the high dose hook effect at elevated 
concentrations.  
 
 D-dimer is one of many indicators that is used to determine postmortem blood. 
Other indicators, such as pH value and concentration of myoglobin contents, may allow 
postmortem blood to be differentiated from other types of blood, especially from menstrual 
blood. However, it is important to have the medical history of the individual if possible, 
since the presence of D-dimer in the blood is related to a history of previous thrombosis. 
Age is another factor that can influence the D-dimer level in blood. Therefore, quantitating 
D-dimer values across many age groups and over time within individuals would be 
valuable. 
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